The Benefits of High Relaxivity for Brain Tumor Imaging: Results of a Multicenter Intraindividual Crossover Comparison of Gadobenate Dimeglumine with Gadoterate Meglumine (The BENEFIT Study)
Abstract
BACKGROUND AND PURPOSE: Gadobenate dimeglumine (MultiHance) has higher r1 relaxivity than gadoterate meglumine (Dotarem) which may permit the use of lower doses for MR imaging applications. Our aim was to compare 0.1- and 0.05-mmol/kg body weight gadobenate with 0.1-mmol/kg body weight gadoterate for MR imaging assessment of brain tumors.
MATERIALS AND METHODS: We performed crossover, intraindividual comparison of 0.1-mmol/kg gadobenate with 0.1-mmol/kg gadoterate (Arm 1) and 0.05-mmol/kg gadobenate with 0.1-mmol/kg gadoterate (Arm 2). Adult patients with suspected or known brain tumors were randomized to Arm 1 (70 patients) or Arm 2 (107 patients) and underwent 2 identical examinations at 1.5T. The agents were injected in randomized-sequence order, and the 2 examinations were separated by 2–14 days. MR imaging scanners, imaging sequences (T1-weighted spin-echo and T1-weighted high-resolution gradient-echo), and acquisition timing were identical for the 2 examinations. Three blinded readers evaluated images for diagnostic information (degree of definition of lesion extent, lesion border delineation, visualization of lesion internal morphology, contrast enhancement) and quantitatively for percentage lesion enhancement and lesion-to-background ratio. Safety assessments were performed.
RESULTS: In Arm 1, a highly significant superiority (P < .002) of 0.1-mmol/kg gadobenate was demonstrated by all readers for all end points. In Arm 2, no significant differences (P > .1) were observed for any reader and any end point, with the exception of percentage enhancement for reader 2 (P < .05) in favor of 0.05-mmol/kg gadobenate. Study agent–related adverse events were reported by 2/169 (1.2%) patients after gadobenate and by 5/175 (2.9%) patients after gadoterate.
CONCLUSIONS: Significantly superior morphologic information and contrast enhancement are demonstrated on brain MR imaging with 0.1-mmol/kg gadobenate compared with 0.1-mmol/kg gadoterate. No meaningful differences were recorded between 0.05-mmol/kg gadobenate and 0.1-mmol/kg gadoterate.
Abbreviations
- GBCA
- gadolinium-based contrast agent
- LBR
- lesion-to-background ratio
- SI
- signal intensity
- T1GRE
- T1-weighted high resolution gradient-echo
- T1SE
- T1-weighted spin-echo
- © 2015 American Society of Neuroradiology
Indicates open access to non-subscribers at www.ajnr.org
Jump to section
Related Articles
- No related articles found.
Cited By...
- Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration
- Safety and Diagnostic Efficacy of Gadobenate Dimeglumine in MRI of the Brain and Spine of Neonates and Infants
- T1 Signal Measurements in Pediatric Brain: Findings after Multiple Exposures to Gadobenate Dimeglumine for Imaging of Nonneurologic Disease
- Reply:
- Re: The Benefits of High Relaxivity for Brain Tumor Imaging: Results of a Multicenter Intraindividual Crossover Comparison of Gadobenate Dimeglumine with Gadoterate Meglumine (The BENEFIT Study)
This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.
- Timothy J Kaufmann, Marion Smits, Jerrold Boxerman, Raymond Huang, Daniel P Barboriak, Michael Weller, Caroline Chung, Christina Tsien, Paul D Brown, Lalitha Shankar, Evanthia Galanis, Elizabeth Gerstner, Martin J van den Bent, Terry C Burns, Ian F Parney, Gavin Dunn, Priscilla K Brastianos, Nancy U Lin, Patrick Y Wen, Benjamin M EllingsonNeuro-Oncology 2020 22 6
- Eric M. Gale, Peter Caravan, Anil G. Rao, Robert J. McDonald, Matthew Winfeld, Robert J. Fleck, Michael S. GeePediatric Radiology 2017 47 5
- Val M. Runge, Johannes T. HeverhagenInvestigative Radiology 2018 53 7
- G.K. Schneider, J. Stroeder, G. Roditi, C. Colosimo, P. Armstrong, M. Martucci, A. Buecker, P. RaczeckAmerican Journal of Neuroradiology 2017 38 9
- Huanyu Luo, Tao Zhang, Nan-Jie Gong, Jonthan Tamir, Srivathsa Pasumarthi Venkata, Cheng Xu, Yunyun Duan, Tao Zhou, Fuqing Zhou, Greg Zaharchuk, Jing Xue, Yaou LiuEuropean Radiology 2021 31 9
- Rajat Chauhan, Nagwa El-Baz, Robert S. Keynton, Kurtis T. James, Danial A. Malik, Mingming Zhu, Ayman El-Baz, Chin K. Ng, Paula J. Bates, Mohammad Tariq Malik, Martin G. O’TooleNanomaterials 2019 9 5
- Simona Bussi, Laure Penard, Roberta Bonafè, Catherine Botteron, Roberto Celeste, Alessandra Coppo, Roberta Queliti, Miles A. Kirchin, Fabio Tedoldi, Federico MaisanoRegulatory Toxicology and Pharmacology 2018 92
- Paola Clauser, Thomas H. Helbich, Panagiotis Kapetas, Katja Pinker, Maria Bernathova, Ramona Woitek, Andreas Kaneider, Pascal A.T. BaltzerJournal of Magnetic Resonance Imaging 2019 49 4
- Girolamo Crisi, Silvano Filice, Gunter Erb, Francesca BozzettiJournal of Magnetic Resonance Imaging 2017 45 2
- Helena M. Dekker, Gerard J. Stroomberg, Aart J. Van der Molen, Mathias ProkopInsights into Imaging 2024 15 1